Over 12 months, Cartesian Therapeutics, Inc. saw more selling than buying from its insiders — purchases of about $206,000 against sales of $259,000.
The largest purchase came from BARABE TIMOTHY C (Director), about $206,000.
Big money check: 95 institutions held RNAC as of Q2 2026, and more funds bought than sold. No open-market insider buying or selling in the last full quarter. Insiders bought in 3 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Jan 8, 2026 | Brunn Carsten | CEO | Sell | 23,766 | $6.82 | $162K | SEC |
| Jan 8, 2026 | Miljkovic Milos | Executive Officer | Sell | 3,573 | $6.82 | $24K | SEC |
| Jan 8, 2026 | Davis Blaine | CFO | Sell | 10,591 | $6.82 | $72K | SEC |
| Dec 8, 2025 | BARABE TIMOTHY C | Director | Buy | 30,000 | $6.86 | $206K | SEC |
| Apr 11, 2025 | SPRINGER TIMOTHY A | Director | Buy | 45,144 | $10.43 | $471K | SEC |
| Apr 11, 2025 | SPRINGER TIMOTHY A | Director | Buy | 31 | $9.95 | $308 | SEC |
| Apr 11, 2025 | SPRINGER TIMOTHY A | Director | Buy | 178 | $9.95 | $2K | SEC |
| Apr 11, 2025 | SPRINGER TIMOTHY A | Director | Buy | 7,966 | $10.43 | $83K | SEC |
| Apr 11, 2025 | SPRINGER TIMOTHY A | Director | Buy | 609 | $10.92 | $7K | SEC |
| Apr 11, 2025 | SPRINGER TIMOTHY A | Director | Buy | 41,604 | $9.43 | $392K | SEC |
| Apr 11, 2025 | SPRINGER TIMOTHY A | Director | Buy | 3,451 | $10.92 | $38K | SEC |
| Apr 11, 2025 | SPRINGER TIMOTHY A | Director | Buy | 6,412 | $10.77 | $69K | SEC |
| Apr 11, 2025 | SPRINGER TIMOTHY A | Director | Buy | 36,338 | $10.77 | $391K | SEC |
| Apr 11, 2025 | SPRINGER TIMOTHY A | Director | Buy | 7,342 | $9.43 | $69K | SEC |
| Mar 20, 2025 | SPRINGER TIMOTHY A | Director | Buy | 14,740 | $14.42 | $213K | SEC |
In the last 12 months Cartesian Therapeutics, Inc. insiders made open-market purchases worth about $206,000 and sales worth about $259,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in RNAC was filed on 2026-01-08.
95 investment managers reported holding RNAC in SEC Form 13F filings for Q2 2026.
No congressional trades in RNAC were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).